GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says

Deutsche Bank analyst Emmanuel Papadakis reviewed GSK’s phase II mRNA flu vaccine data presented at the OPTIONS XIII Conference, noting the results closely resemble Moderna’s corresponding candidate. The takeaway is supportive for GSK’s clinical signal, though no efficacy endpoints, magnitude, or guidance changes were provided in the article. Overall, this is modestly positive investor sentiment with limited expected near-term price impact.